CIO
MARCH 4, 2025
From AI models that boost sales to robots that slash production costs, advanced technologies are transforming both top-line growth and bottom-line efficiency. Business leaders dont need to be technology experts to grasp this shift; they need vision and urgency. Pharma and agriculture companies now leverage AI and gene-editing (e.g.,
Crunchbase News
NOVEMBER 1, 2024
startups raised half a billion dollars apiece, and another eight raised $100 million or more, with industries from cybersecurity to biotech to AI represented. The latest startup in the space to get a big chunk of cash is Beta Technologies, maker of electric vertical take-off and landing planes. billion valuation in the process.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Ooda Loop
JANUARY 15, 2025
Commerce Department said Wednesday it is imposing new export controls on biotechnology equipment and related technology because of national security concerns tied to artificial intelligence and data science. technology to strengthen military capabilities and help design new weapons through AI.
TechCrunch
JULY 16, 2021
2021 should be a banner year for biotech startups that make smart choices early. After a record year for biotech investment in 2020 — during which the industry saw $28.5 Since 1996 , 14,000 startups have licensed technology out of those universities, and 67% of licenses were taken by startups or small companies. Kevin O’Connor.
TechCrunch
DECEMBER 15, 2022
That’s why we weren’t very surprised when a slew of investors told us they rarely see a biotech startup that doesn’t incorporate AI in some form or other these days. But despite becoming quite the buzzword, AI’s apparent ubiquity in biotech isn’t actually driving deal flow or higher valuations.
Crunchbase News
DECEMBER 3, 2024
Given this success, many biotech companies are looking to move on to the next phase of their organizational growth — which may mean an initial public offering. As optimism grows, market conditions may stabilize in 2025 — particularly in the wake of the recent interest rate cuts — and more biotech companies may consider offerings.
TechCrunch
MARCH 16, 2023
James Coates is the Health and Human Performance principal at Decisive Point , a venture capital and advisory firm that invests in and supports startups with emerging defense technologies. This is especially true for biotech startups, where investment needs are higher and success timelines can be much longer.
Expert insights. Personalized for you.
177 
Let's personalize your content